Beta Bionics (NASDAQ:BBNX) Shares Down 9.2% Following Analyst Downgrade

Beta Bionics, Inc. (NASDAQ:BBNX) shares were down 9.2% on Monday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The company traded as low as $17.83 and last traded at $18.28. Approximately 378,461 shares traded hands during trading, a decline of 78% from the average daily volume of 1,697,192 shares. The stock had previously closed at $20.14.

Several other research analysts also recently issued reports on the company. The Goldman Sachs Group upped their price objective on Beta Bionics from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Robert W. Baird set a $28.00 price target on Beta Bionics in a report on Tuesday, December 16th. Lake Street Capital boosted their price objective on Beta Bionics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Friday. Piper Sandler restated an “overweight” rating and issued a $32.00 target price (up previously from $26.00) on shares of Beta Bionics in a report on Wednesday, October 29th. Finally, Truist Financial increased their price target on Beta Bionics from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and an average target price of $30.20.

Insider Activity

In other Beta Bionics news, Director Maria Palasis sold 1,406 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the transaction, the director owned 9,841 shares in the company, valued at approximately $264,821.31. This represents a 12.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 35,302 shares of company stock valued at $1,036,449.

Hedge Funds Weigh In On Beta Bionics

Hedge funds have recently bought and sold shares of the company. Divisadero Street Capital Management LP purchased a new stake in Beta Bionics during the second quarter valued at approximately $13,817,000. Goldman Sachs Group Inc. purchased a new position in shares of Beta Bionics in the 1st quarter worth approximately $715,000. Palumbo Wealth Management LLC bought a new position in shares of Beta Bionics during the 2nd quarter valued at approximately $431,000. Sands Capital Alternatives LLC raised its holdings in Beta Bionics by 15.0% during the 2nd quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock valued at $51,981,000 after buying an additional 466,331 shares during the period. Finally, Walleye Capital LLC raised its holdings in Beta Bionics by 47.3% during the 2nd quarter. Walleye Capital LLC now owns 218,189 shares of the company’s stock valued at $3,177,000 after buying an additional 70,084 shares during the period.

Beta Bionics Price Performance

The business has a 50-day moving average of $29.28 and a 200-day moving average of $22.37. The company has a market capitalization of $806.98 million and a P/E ratio of -4.19.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.12. Beta Bionics had a negative net margin of 87.89% and a negative return on equity of 35.72%. The business had revenue of $27.25 million during the quarter, compared to the consensus estimate of $23.92 million.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.